Anixa Biosciences Inc. has announced the completion of the final patient visit in its Phase 1 clinical trial evaluating a novel breast cancer vaccine developed in collaboration with Cleveland Clinic. The vaccine, designed to stimulate the immune system to recognize and target breast cancer, was administered to 35 women across three cohorts: individuals with a history of triple-negative breast cancer (TNBC), women at elevated genetic risk who elected preventive mastectomy, and patients receiving the vaccine in combination with pembrolizumab. Preliminary data indicate the vaccine is well tolerated, with more than 70% of participants showing protocol-defined immune responses. Comprehensive immune response and safety data from the trial will be presented at the San Antonio Breast Cancer Symposium on December 11, 2025. A final study report will be submitted to the U.S. Department of Defense, and a Clinical Study Report will be filed with the U.S. Food and Drug Administration.